Curcio Claudia, Di Carlo Emma, Clynes Raphael, Smyth Mark J, Boggio Katia, Quaglino Elena, Spadaro Michela, Colombo Mario P, Amici Augusto, Lollini Pier-Luigi, Musiani Piero, Forni Guido
Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.
J Clin Invest. 2003 Apr;111(8):1161-70. doi: 10.1172/JCI17426.
Since the mechanisms by which specific immunity destroys Her-2/neu carcinoma cells are highly undetermined, these were assessed in BALB/c mice vaccinated with plasmids encoding extracellular and transmembrane domains of the protein product (p185(neu)) of the rat Her-2/neu oncogene shot into the skin by gene gun. Vaccinated mice rejected a lethal challenge of TUBO carcinoma cells expressing p185(neu). Depletion of CD4 T cells during immunization abolished the protection, while depletion of CD8 cells during the effector phase halved it, and depletion of polymorphonuclear granulocytes abolished all protection. By contrast, Ig mu-chain gene KO mice, as well as Fcgamma receptor I/III, beta-2 microglobulin, CD1, monocyte chemoattractant protein 1 (MCP1), IFN-gamma, and perforin gene KO mice were protected. Only mice with both IFN-gamma and perforin gene KOs were not protected. Although immunization also cured all BALB/c mice bearing established TUBO carcinomas, it did not cure any of the perforin KO or perforin and IFN-gamma KO mice. Few mice were cured that had knockouts of the gene for Ig mu-chain, Fcgamma receptor I/III, IFN-gamma, or beta-2 microglobulin. Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185(neu) carcinomas involves distinct mechanisms, each endowed with a different curative potential.
由于特异性免疫破坏Her-2/neu癌细胞的机制高度不确定,因此在通过基因枪将编码大鼠Her-2/neu癌基因蛋白产物(p185(neu))的细胞外和跨膜结构域的质粒注射到皮肤中的BALB/c小鼠中对这些机制进行了评估。接种疫苗的小鼠排斥表达p185(neu)的TUBO癌细胞的致死性攻击。免疫期间CD4 T细胞的耗竭消除了保护作用,而效应期CD8细胞的耗竭使其减半,多形核粒细胞的耗竭则消除了所有保护作用。相比之下,Ig μ链基因敲除小鼠以及Fcγ受体I/III、β2微球蛋白、CD1、单核细胞趋化蛋白1(MCP1)、IFN-γ和穿孔素基因敲除小鼠受到了保护。只有IFN-γ和穿孔素基因双敲除的小鼠没有受到保护。尽管免疫也治愈了所有携带已建立的TUBO癌的BALB/c小鼠,但它没有治愈任何穿孔素基因敲除或穿孔素和IFN-γ基因双敲除的小鼠。很少有Ig μ链、Fcγ受体I/III、IFN-γ或β2微球蛋白基因敲除的小鼠被治愈。此外,疫苗接种治愈了一半的CD1基因敲除小鼠和大多数MCP1基因敲除小鼠。根除已建立的p185(neu)癌涉及不同的机制,每种机制具有不同的治愈潜力。